ImmunoGen Grants Lilly Exclusive Research, Development, and Commercialization License in $1.7+ Billion ADC Deal

ImmunoGen and Eli Lilly and Company have entered into an agreement that gives Lilly exclusive rights to research, develop, and commercialize ADCs designed for targets selected by Lilly from ImmunoGen’s camptothecin technology.